Pregabalin controlled-release - Pfizer

Drug Profile

Pregabalin controlled-release - Pfizer

Alternative Names: GRO 12 - Pfizer; MR-1- Pfizer; MR-2- Pfizer; Pregabalin CR; Pregabalin ER

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Anxiolytics; Neuroprotectants; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Fibromyalgia; Postherpetic neuralgia
  • No development reported Epilepsy

Most Recent Events

  • 30 Jun 2016 Pfizer completes a phase I bioequivalence trial in Healthy volunteers in USA (PO, Controlled-release) (NCT02725112)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Feb 2016 Pfizer initiates a phase I bioequivalence trial in Healthy volunteers in USA (PO, Controlled-release) (NCT02725112)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top